|
Nancy T. Chang is Managing Director at OrbiMed Advisors, a preeminent global health-sciences asset management firm. Previously, Dr. Chang was the Co-Founder, Chief Executive Officer and Chairman of the Board at Tanox, Inc., which was created to address significant unmet medical needs in the areas of asthma, allergy, inflammation and diseases affecting the human immune system. In 2000 she took Tanox public, raising $244 million, which was the second-largest initial public offering ever for a biopharmaceutical company at that time. Dr. Chang has been an active member in the biopharmaceutical industry for more than 25 years. She has published more than 35 papers on topics ranging from monoclonal antibodies to HIV and holds seven patents. She currently serves on the Boards of Directors of the Federal Reserve Bank of Houston, BioHouston, the Center of Houston’s Future and the Greater Houston Partnership. Dr. Chang has been a director since 2007. | 